Sector News

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

January 17, 2021
Life sciences

Sanofi has signed an agreement to acquire clinical-stage biopharmaceutical company Kymab for an upfront payment of about $1.1bn in cash.

The deal also includes payment of up to $350m on achieving particular milestones.

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

Sanofi CEO Paul Hudson said: “The Kymab acquisition adds KY1005 to our dynamic pipeline, a potential first-in-class treatment for a range of immune and inflammatory diseases.

“The novel mechanism of action may provide treatment for patients with suboptimal responses to available therapies. We look forward to rapidly developing this investigational medicine.”

Last August, Kymab reported that KY1005 met both primary endpoints in a Phase IIa trial that analysed patients with moderate to severe atopic dermatitis.

Kymab’s pipeline also has an ICOS agonist monoclonal antibody, KY1044, which is currently in early Phase I / II development as monotherapy and in combination with an anti-PD-L1.

As well as this oncology asset, Sanofi will have access to Kymab’s latest antibody technologies and research capabilities.

Kymab CEO Simon Sturge said: “The agreement is a testament to the commitment, drive and expertise of the entire Kymab team and we are pleased to receive this endorsement from Sanofi.

“With its significant global resources, we believe Sanofi is the perfect partner to progress Kymab’s pipeline of products and the merger will expedite the time it takes for our novel therapies to get to patients.”

Last November, Sanofi signed a definitive agreement to acquire the entire share capital of Kiadis Pharma in a deal valued at approximately €308m ($359m).

Sanofi anticipates concluding the deal in the first half of this year.

by Pharmaceutical-Technology.com

Source: pharmaceutical-technology.com

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach